CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by alphaflighton Jun 15, 2021 9:06am

897 Views

Post# 33387303

Graycliff Intersecting High-Grade Au Intervals Near Surface

Graycliff Exploration Continues Intersecting

High-Grade Gold Intervals Near Surface Including

52 g/t Gold Over 4.0 Metres

TORONTO, ON – June 15, 2021 - Graycliff Exploration Limited (the “Company” or “Graycliff”) (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) is pleased to announce limited assay results of the second drill hole from its phase two core drilling program (see Press Release dated April 22, 2021) on the Company’s Shakespeare Gold Project located on the prolific Canadian Shield near Sudbury, Ontario.

“It would appear that as assay labs are overwhelmed with the shear volume of material they are receiving, the Company is once again in a position where it needs to release partial results from its drill holes. We still do not have the rest of the samples from Holes J-8-21 and J-9-21, but they should be available later in Q2. Obviously, further confirmation of exceptional high-grade results is getting us extremely excited about the potential results that the 3D modelling will show following the receipt of all of the results from our phase two drilling program,” stated President and CEO, James Macintosh.

The two high-grade gold intersections intersected drill hole J-9-21 is located approximately 20 m down-dip of the mineralization reported from drill hole J-8-20 that highlighted an interval grading 67 g/t Au over 3m and both holes J-8-21 and J-9-21 are below hole J-7-20 (see Cross Section “A-A” in Press Release dated March 24, 2021). Sample materials from several other drill holes have been delivered to the assay lab and those assay results are expected to be available in somewhat regular intervals over the coming weeks.

Qualified Person

Bruce Durham, P.Geo, is a Qualified Person, as that term is defined by Canadian regulatory guidelines under NI 43-101, and has read and approved the technical information contained in this press release.

QA/QC Protocol:

https://graycliffexploration.com/wp-content/uploads/2021/06/graycliffexploration-qa-qc-protocols-june-2021.pdf

About Graycliff Exploration Limited.

Graycliff Exploration is a mineral exploration company focused on its 1,025 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company's Shakespeare Project consists of one crown patented lease, two crown leases and 40 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907. Graycliff’s Baldwin Project is adjacent to the east and is comprised of 68 claims covering 1,500 hectares. This brings our total land package in the area to 2,525 hectares.